Does the media favor NVAX or ACHV?

In the previous week, Novavax had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 6 mentions for Novavax and 3 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.46 beat Novavax's score of 0.09 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INVA or ACHV?

In the previous week, Innoviva had 7 more articles in the media than Achieve Life Sciences. MarketBeat recorded 10 mentions for Innoviva and 3 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.46 beat Innoviva's score of -0.10 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MNKD or ACHV?

In the previous week, MannKind had 5 more articles in the media than Achieve Life Sciences. MarketBeat recorded 8 mentions for MannKind and 3 mentions for Achieve Life Sciences. MannKind's average media sentiment score of 0.74 beat Achieve Life Sciences' score of 0.46 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ACHV or ZBIO more profitable?

Zenas BioPharma's return on equity of -99.99% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -193.49% -111.88% Zenas BioPharma N/A -99.99% -58.06%

Does the media refer more to ACHV or ZBIO?

In the previous week, Achieve Life Sciences had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 3 mentions for Achieve Life Sciences and 2 mentions for Zenas BioPharma. Achieve Life Sciences' average media sentiment score of 0.46 beat Zenas BioPharma's score of 0.45 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ACHV or OPK?

In the previous week, OPKO Health had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 4 mentions for OPKO Health and 3 mentions for Achieve Life Sciences. OPKO Health's average media sentiment score of 1.32 beat Achieve Life Sciences' score of 0.46 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Achieve Life Sciences (ACHV) Competitors

$5.48 +0.35 (+6.82%)

Closing price 04:00 PM Eastern

Extended Trading

$5.28 -0.20 (-3.67%)

As of 07:56 PM Eastern

Compare

ACHV vs. NVAX, INVA, MNKD, ZBIO, and OPK

Should you buy Achieve Life Sciences stock or one of its competitors? MarketBeat compares Achieve Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Achieve Life Sciences include Novavax (NVAX), Innoviva (INVA), MannKind (MNKD), Zenas BioPharma (ZBIO), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Achieve Life Sciences compare to Novavax?

Novavax (NASDAQ:NVAX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novavax has higher revenue and earnings than Achieve Life Sciences. Novavax is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.26	$440.30M	-$0.58	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Novavax currently has a consensus target price of $12.13, suggesting a potential upside of 40.66%. Achieve Life Sciences has a consensus target price of $14.67, suggesting a potential upside of 167.64%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Novavax had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 6 mentions for Novavax and 3 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.46 beat Novavax's score of 0.09 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novavax beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Innoviva?

Innoviva (NASDAQ:INVA) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Innoviva has a net margin of 119.89% compared to Achieve Life Sciences' net margin of 0.00%. Innoviva's return on equity of 33.33% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Achieve Life Sciences	N/A	-193.49%	-111.88%

In the previous week, Innoviva had 7 more articles in the media than Achieve Life Sciences. MarketBeat recorded 10 mentions for Innoviva and 3 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.46 beat Innoviva's score of -0.10 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market.

Innoviva currently has a consensus price target of $36.20, indicating a potential upside of 62.11%. Achieve Life Sciences has a consensus price target of $14.67, indicating a potential upside of 167.64%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Innoviva has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.01	$271.17M	$6.01	3.72
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Summary

Innoviva beats Achieve Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to MannKind?

MannKind (NASDAQ:MNKD) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, MannKind had 5 more articles in the media than Achieve Life Sciences. MarketBeat recorded 8 mentions for MannKind and 3 mentions for Achieve Life Sciences. MannKind's average media sentiment score of 0.74 beat Achieve Life Sciences' score of 0.46 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has higher revenue and earnings than Achieve Life Sciences. MannKind is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.00	$5.86M	-$0.07	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Achieve Life Sciences has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Achieve Life Sciences	N/A	-193.49%	-111.88%

49.6% of MannKind shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MannKind has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market.

MannKind presently has a consensus price target of $8.97, suggesting a potential upside of 164.56%. Achieve Life Sciences has a consensus price target of $14.67, suggesting a potential upside of 167.64%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

MannKind beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Zenas BioPharma?

Achieve Life Sciences (NASDAQ:ACHV) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Zenas BioPharma's return on equity of -99.99% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Zenas BioPharma	N/A	-99.99%	-58.06%

Achieve Life Sciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market.

33.5% of Achieve Life Sciences shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Achieve Life Sciences currently has a consensus target price of $14.67, indicating a potential upside of 167.64%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 151.48%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Achieve Life Sciences is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Achieve Life Sciences has higher earnings, but lower revenue than Zenas BioPharma. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Zenas BioPharma	$10M	111.17	-$377.74M	-$8.47	N/A

In the previous week, Achieve Life Sciences had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 3 mentions for Achieve Life Sciences and 2 mentions for Zenas BioPharma. Achieve Life Sciences' average media sentiment score of 0.46 beat Zenas BioPharma's score of 0.45 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Achieve Life Sciences beats Zenas BioPharma on 9 of the 15 factors compared between the two stocks.

How does Achieve Life Sciences compare to OPKO Health?

Achieve Life Sciences (NASDAQ:ACHV) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Achieve Life Sciences has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

In the previous week, OPKO Health had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 4 mentions for OPKO Health and 3 mentions for Achieve Life Sciences. OPKO Health's average media sentiment score of 1.32 beat Achieve Life Sciences' score of 0.46 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OPKO Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
OPKO Health	-36.63%	-16.78%	-10.98%

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 49.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Achieve Life Sciences presently has a consensus price target of $14.67, indicating a potential upside of 167.64%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 8.39%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Achieve Life Sciences has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
OPKO Health	$606.90M	1.78	-$225.68M	-$0.27	N/A

Summary

Achieve Life Sciences and OPKO Health tied by winning 8 of the 16 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$526.64M	$2.96B	$6.49B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.57%
P/E Ratio	-4.89	17.68	23.92	23.74
Price / Sales	N/A	288.30	507.57	108.00
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	13.70	3.83	10.28	6.78
Net Income	-$54.65M	$75.85M	$3.57B	$337.51M
7 Day Performance	3.40%	-4.52%	-1.43%	-2.72%
1 Month Performance	5.18%	-5.85%	3.27%	1.87%
1 Year Performance	43.08%	15.31%	23.37%	26.60%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	2.4268 of 5 stars	$5.48 +6.8%	$14.67 +167.6%	+33.9%	$526.64M	N/A	N/A	20
NVAX Novavax	2.4144 of 5 stars	$10.51 -4.2%	$12.13 +15.4%	+27.4%	$1.80B	$1.12B	N/A	1,990
INVA Innoviva	3.1591 of 5 stars	$21.51 +0.4%	$36.20 +68.3%	+4.4%	$1.59B	$420.69M	3.58	100	News Coverage Analyst Upgrade High Trading Volume
MNKD MannKind	4.1567 of 5 stars	$3.53 -6.4%	$8.97 +154.1%	-22.4%	$1.16B	$348.97M	N/A	400	Analyst Upgrade
ZBIO Zenas BioPharma	3.6664 of 5 stars	$18.17 -1.3%	$44.29 +143.7%	+57.1%	$1.16B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. NVAX, INVA, MNKD, ZBIO, and OPK

How does Achieve Life Sciences compare to Novavax?

Summary

How does Achieve Life Sciences compare to Innoviva?

Summary

How does Achieve Life Sciences compare to MannKind?

Summary

How does Achieve Life Sciences compare to Zenas BioPharma?

Summary

How does Achieve Life Sciences compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. NVAX, INVA, MNKD, ZBIO, and OPK

How does Achieve Life Sciences compare to Novavax?

Do insiders and institutionals hold more shares of NVAX or ACHV?

Which has stronger valuation & earnings, NVAX or ACHV?

Which has more volatility and risk, NVAX or ACHV?

Is NVAX or ACHV more profitable?

Do analysts prefer NVAX or ACHV?

Does the media favor NVAX or ACHV?

Summary

How does Achieve Life Sciences compare to Innoviva?

Do insiders and institutionals believe in INVA or ACHV?

Is INVA or ACHV more profitable?

Does the media favor INVA or ACHV?

Which has more risk & volatility, INVA or ACHV?

Do analysts recommend INVA or ACHV?

Which has higher earnings & valuation, INVA or ACHV?

Summary

How does Achieve Life Sciences compare to MannKind?

Does the media prefer MNKD or ACHV?

Which has better valuation & earnings, MNKD or ACHV?

Is MNKD or ACHV more profitable?

Do institutionals and insiders hold more shares of MNKD or ACHV?

Which has more volatility & risk, MNKD or ACHV?

Do analysts rate MNKD or ACHV?

Summary

How does Achieve Life Sciences compare to Zenas BioPharma?

Is ACHV or ZBIO more profitable?

Which has more risk & volatility, ACHV or ZBIO?

Do insiders and institutionals believe in ACHV or ZBIO?

Do analysts rate ACHV or ZBIO?

Which has higher valuation & earnings, ACHV or ZBIO?

Does the media refer more to ACHV or ZBIO?

Summary

How does Achieve Life Sciences compare to OPKO Health?

Which has more risk and volatility, ACHV or OPK?

Does the media refer more to ACHV or OPK?

Is ACHV or OPK more profitable?

Do institutionals & insiders believe in ACHV or OPK?

Do analysts rate ACHV or OPK?

Which has preferable valuation and earnings, ACHV or OPK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools